Navigation Links
AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain

n Rating Scale scores over the same time period as reported in the primary efficacy analysis.

-- Categorical analysis of the Pain Relief Rating Scale scores averaged at three months showed that almost twice as many patients in each of the Zenvia treatment groups obtained "a lot" of or "complete" pain relief as that in the placebo group.

-- Active treatment with both Zenvia doses significantly reduced pain interference with daily activities compared with placebo (p less than 0.0001).

-- Active treatment with both Zenvia doses significantly reduced pain interference with sleep compared with placebo (p less than 0.0001).

-- The consistency for reduced pain interference with both daily activities and reduced sleep interference across time periods during the study suggests that the benefits of Zenvia relative to placebo were maintained over the entire study period.

-- The magnitude of the improvements in quality-of-life with Zenvia was approximately 50% greater than that obtained with placebo (p=0.05 for DM/Q 45 and p=0.08 for DM/Q 30).

Cardiovascular findings were assessed by EKGs at screening, as well as clinical visits at day 1, 15 and 92. At day 15 the mean change in QTc interval compared to the screening visit was 1 millisecond in both treatment groups, versus a mean change in QTc interval of -2 milliseconds for placebo. At day 92 the mean change in QTc intervals was 5 and 2 milliseconds in the DM/Q 45 and DM/Q 30 treatment groups, respectively compared to the screening visit, versus a mean change in QTc interval of -2 milliseconds for placebo. These increases were consistent with what has been observed in previous studies. There were no cases of Torsade de Pointes or sudden death reported. The most commonly reported adverse events from this Phase III study were dizziness, nausea, diarrhea, fatigue and somnolence which were mild to moderate in nature. A higher number of patients in the DM/Q 45 and DM/Q 30 treatment groups (2
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic Peripheral Neuropathic Pain at Second International Congress on Neuropathic Pain
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:12/16/2009)... Mich., Dec. 16 GlaxoSmithKline plc [GSK] ... today announced an exclusive licensing agreement in the ... use of NB-001, a novel, patented compound representing ... sores. Developed by NanoBio, NB-001 provides significant antimicrobial ... herpes labialis . ,, Cold sores ...
(Date:12/16/2009)... CORALVILLE, Iowa, Dec. 16 Vivakor, ... a Business Development agreement with Baker Consulting ... affiliate group, Kyouko Group, Inc. out of ... retained by Vivakor to assist with business ... its recently reported acquisition strategy. Specifically, Baker ...
(Date:12/16/2009)... Frost & Sullivan,s ... to speaking at the 2010 International Consumer ... January 9, 2010 in Las Vegas. ... of consumer-based digital health and wellness devices, ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, Bujnoch focuses on patient ...
Breaking Medicine Technology:GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment 2Vivakor Signs Business Development Agreement With Baker Consulting 2Frost & Sullivan to Speak at 2010 International Consumer Electronics Digital Health Summit 2For Organ Donation Intent and Reality Dont Align 56981 1For Organ Donation Intent and Reality Dont Align 56981 2For Organ Donation Intent and Reality Dont Align 56981 3H1N1 frenzy may allow regular flu to be more deadly than ever 56980 1H1N1 frenzy may allow regular flu to be more deadly than ever 56980 2Early spring time for Edinburgh 3F Study predicts effect of global warming on spring flowers 9896 1Early spring time for Edinburgh 3F Study predicts effect of global warming on spring flowers 9896 2
... HOUSTON, LONDON and RESEARCH TRIANGLE PARK, N.C., Nov. ... (NYSE: GSK ),announced today that the U.S. ... approvable letter for the new drug application for ... of adults with major,depressive disorder. The FDA ...
... Nov. 2 GeoVax Labs, Inc. (OTC,Bulletin Board: ... safety and immunogenicity data from its full-dose HIV/AIDS,vaccine ... This full-dose trial is the second in a ... test the safety and immunogenicity of the GeoVax,HIV/AIDS ...
Other Medicine Technology:Fabre Kramer Pharmaceuticals Receives Decision From FDA on Gepirone ER for Major Depressive Disorder 2Excellent Results Received from GeoVax's Full-Dose HIV/AIDS Vaccine Trial 2Excellent Results Received from GeoVax's Full-Dose HIV/AIDS Vaccine Trial 3Excellent Results Received from GeoVax's Full-Dose HIV/AIDS Vaccine Trial 4
(Date:12/16/2009)... of C3: Colorectal Cancer Coalition,s advocacy efforts, $15 million ... included in the final Fiscal Year 2010 Defense Appropriations ... research cancers, like colorectal cancer, that are not addressed ... programs run by the U.S. Army Medical Research and ... funding for this new cancer research program was included ...
(Date:12/16/2009)... is long-term goal, researchers say , , WEDNESDAY, Dec. ... to predict whether a patient will suffer a second ... "This is an important new tool because studies have ... after a first stroke are more likely to die ... General Hospital and Harvard Medical School, said in an ...
(Date:12/16/2009)... plays a role in reducing inflammation in the lungs ... variant that plays a role in inflammation seems to ... as adults who smoke. , Researchers also found that ... had a lower risk of developing chronic obstructive pulmonary ... smoking. , "The gene seems to be protective of ...
(Date:12/16/2009)... health and environmental concerns about the emerging nanotechnology industry, ... behavior of nanoparticles in municipal sewage treatment plants ... published in ACS, journal Environmental Science & Technology ... Ecology and Hydrology and colleagues note that experts predict ... less than 1/1000th the width of a human hair ...
(Date:12/16/2009)... commonly found in fatty fish and algae help ... by the American Psychological Association. The finding connects ... people with schizophrenia; bipolar, obsessive-compulsive, and attention-deficit hyperactivity ... nervous system. , The study, reported in ... evidence that fish is brain food. The key ...
Breaking Medicine News(10 mins):Health News:House Creates New Cancer Research Program 2Health News:House Creates New Cancer Research Program 3Health News:New Stroke Tool May Predict Early Recurrence 2Health News:Gene Variant Seems to Guard Against Asthma, COPD 2Health News:Gene Variant Seems to Guard Against Asthma, COPD 3Health News:Behavior modification could ease concerns about nanoparticles 2Health News:New study links DHA type of omega-3 to better nervous-system function 2
... retinopathy who were destined to go blind within five ... treatment with Avastin , a well-known cancer drug, according ... Archives of Ophthalmology. ,This is a major breakthrough ... therapy and commonly develop radiation retinopathy, said Paul T. ...
... where the potentially lethal H5N1 strain of bird flu was ... ,"All the turkeys on the farm have been ... in the area, around 1,000 birds in all," Czech veterinary ... completed today (Friday)," he added. ,The H5N1 strain of ...
... people in Vietnam in the first six months of the ... period last year, the health ministry said Friday. ... 15 percent rise to 19,144 new infections from the mosquito-borne ... delta. ,Malaysia and other Southeast Asian countries have ...
... have formed a new compound AN2690, that might help ... an enzyme crucial for the protein synthesis of fungal ... team of researchers including Dickon Alley and Stephen Cusack ... Biology Laboratory (EMBL) outstation in Grenoble, France. ,AN2690 ...
... an Anglo-American company has been allowed to store white ... by the US Food and Drug Administration. ... immune system that defend the body against both infectious ... take 480-millilitre of blood from interested healthy individuals and ...
... environmental group Friday welcomed the European Union (EU) Parliament's resolution ... the Indian government to do likewise. ,Toxics ... Wednesday. ,The group had called upon governments across ... United Nations Environment Programme (UNEP) in February. ...
Other Medicine News:Health News:Untreatable Eye Disease Improves With Avastin 2Health News:Researchers Devise New Compound to Treat Fungal Infections 2
... your data for future generations. Most gels can ... backing plate of our gel dryer, covering them ... over them to hold the cellophane flat. Tut's ... with an open area somewhat larger than the ...
... large sequencing gels or multiple smaller gels. Rugged design ... lasting durability and corrosion resistance., Large 40 x ... Drying Rate - large sequence gels can be dried ... of temperature and time , Cool-down ...
Inquire...
... and safely, the Hoefer GD 2000 uses a ... beneath the gel through a heavy aluminum platen. ... to 33 x 44 cm in as little ... even heat distribution and even vacuum distribution under ...
Medicine Products: